C. Vázquez

发表

Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer.

L. Ramón, F. España, A. Estellés, 2007, Thrombosis research.

Quantitative real-time reverse transcription-PCR assay for urokinase plasminogen activator, plasminogen activator inhibitor type 1, and tissue metalloproteinase inhibitor type 1 gene expressions in primary breast cancer.

F. España, A. Estellés, R. Castelló, 2002, Clinical chemistry.

Nipple‐sparing mastectomy as treatment for patients with ductal carcinoma in situ: A 10‐year follow‐up study

C. Vázquez, V. Lago, V. Maisto, 2018, The breast journal.

Cytogenetic study of angiosarcoma of the breast

A. Llombart‐Bosch, C. López-Ginés, C. Vázquez, 1994, Genes, chromosomes & cancer.

Epidermal growth factor in human breast cancer, endometrial carcinoma and lung cancer. Its relationship to epidermal growth factor receptor, estradiol receptor and tumor TNM.

J. Garcia-conde, A. Lluch, V. Guillem, 1993, Clinica chimica acta; international journal of clinical chemistry.

DNA/protein ratio as an index of oestrogen receptor content in human breast cancer.

C. Vázquez, P. Bolufer, A. Rodríguez, 1983, European journal of cancer & clinical oncology.

Value of sentinel lymph node biopsy and adjuvant interferon treatment in thick (>4 mm) cutaneous melanoma: an observational study

C. Vázquez, V. Soriano, E. Nagore, 2016, European Journal of Dermatology.

[S100 protein as tumoral marker in melanoma patients. Comparative study with sentinel node biopsy and whole body FDG-PET].

C. Vázquez, B. Ortiz, J. Maíquez, 2003, Revista espanola de medicina nuclear.

Epidermal growth factor receptor in human breast cancer: correlation with cytosolic and nuclear ER receptors and with biological and histological tumor characteristics.

J. Garcia-conde, A. Lluch, F. Miralles, 1990, European journal of cancer.

Specific oncological contribution of cathepsin D and pS2 in human breast cancer: their relationship with TNM status, estradiol receptors, epidermal growth factor receptor and neu amplification.

V. Guillem, J. A. Lopez, B. Munárriz, 1996, Clinica chimica acta; international journal of clinical chemistry.

Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity.

F. España, A. Estellés, R. Castelló, 2006, Thrombosis research.

Anaphylaxis after Peritumoral Injection of Sulphan blue 1 % for Identification of the Sentinel N ode in Lymphatic Mapping of the Breast : Case Report

C. Vázquez, R. Botella-Estrada, María, 2015 .

Estradiol receptors in combination with neu or myc oncogene amplifications might define new subtypes of breast cancer.

A. Ruíz, A. Lluch, C. Vázquez, 1994, Clinica chimica acta; international journal of clinical chemistry.

Cytogenetics, flow cytometry, cytophotometry and morphometry of 22 cases of primary breast carcinoma

A. Llombart‐Bosch, A. Ruíz, A. Pellín, 1992, Virchows Archiv. B, Cell pathology including molecular pathology.

Aromatase activity and estradiol in human breast cancer: its relationship to estradiol and epidermal growth factor receptors and to tumor-node-metastasis staging.

J. Garcia-conde, A. Ruíz, A. Lluch, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

P128 Phase II trial with letrozole (2.8 mg) to maximal response as neoadjuvant endocrine therapy in postmenopausal patients with ER/PgR[+] operable breast cancer

A. Ruíz, C. Vázquez, V. Carañana, 2007 .